Indication
Resectable Pancreatic Cancers
1 clinical trial
2 products
Clinical trial
Feasibility Study of Neoadjuvant Gemcitabine/Nab-Paclitaxel and Hypofractionated Image-Guided Intensity Modulated Radiotherapy in Resectable and Borderline Resectable Pancreatic CancerStatus: Completed, Estimated PCD: 2018-11-07
Product
Gemcitabine/nab-PaclitaxelProduct
Adjuvant chemotherapy